site stats

Intra cellular therapies top shareholders

WebSep 27, 2024 · Intra-Cellular Therapies, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of 9,677,419 shares of common stock, par value $0.0001 per share (the … WebAug 26, 2014 · Industry executive with successful track record on developing and executing strategies to drive innovation, shape corporate strategy, and create new business opportunities in small and large ...

What Kind Of Shareholders Hold The Majority In Intra-Cellular …

WebJun 15, 2024 · Has Intra-Cellular Therapies, Inc. Been A Good Investment? Boasting a total shareholder return of 111% over three years, Intra-Cellular Therapies, Inc. has … WebIntra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. the very revd roger bush https://gmtcinema.com

What Kind Of Investors Own Most Of Intra-Cellular Therapies, Inc ...

WebRegional Business Manager, New England. INTRA-CELLULAR THERAPIES INC. Remote in United States +5 locations. Estimated $90.2K - $114K a year. WebApr 10, 2024 · ITCI Stock Overview. Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system … WebDec 5, 2024 · We did this open-label, cluster-randomised trial (DiRECT) at 49 primary care practices in Scotland and the Tyneside region of England. Practices were randomly assigned (1:1), via a computer-generated list, to provide either a weight management programme (intervention) or best-practice care by guidelines (control), with stratification … the very revd dr robert willis

Park Avenue Securities LLC Has $256,000 Stock Position in Intra ...

Category:Intra Cellular Therapies Jobs, Employment Indeed.com

Tags:Intra cellular therapies top shareholders

Intra cellular therapies top shareholders

Is Intra-Cellular Therapies

Web1 day ago · April 13, 2024. Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on ... WebTel +1 248 290 5400. Fax +1 248 290 5401. Email [email protected]. Purpose: Tardive dyskinesia (TD) is a hyperkinetic movement disorder in which patients experience abnormal involuntary movements that can have profound negative impacts on physical, cognitive, and psychosocial functioning. Use of measures to assess the …

Intra cellular therapies top shareholders

Did you know?

WebIntra Cellular Therapies (NASDAQ: ITCI) is owned by 87.14% institutional shareholders, 25.82% Intra Cellular Therapies insiders, and 0.00% retail investors. Christopher D. Alafi is the largest individual Intra Cellular Therapies shareholder, owning 5.86M shares representing 6.15% of the company. WebMar 31, 2024 · Intra-Cellular Therapies, Inc. is a biopharmaceutical company. The Company is focused on the discovery, clinical development and commercialization of …

Web/ Intra-Cellular Therapies, Inc. Intra-Cellular Therapies, Inc. Website. Get a D&B Hoovers Free Trial. ... Shareholders Equity; All financial statement data is in millions except per share data Source: ... D&B Hoovers TM Wins 3 Best Of Awards from TrustRadius! Award-Winning Sales Intel. WebMar 1, 2024 · NEW YORK, March 01, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc., (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced its financial results for the fourth quarter and year ended December 31, 2024 …

WebAug 15, 2024 · Some Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) shareholders may be a little concerned to see that the Independent Director, Joel Marcus, recently sold a substantial US$592k worth of stock at a ...

WebApr 14, 2024 · Knights of Columbus Asset Advisors LLC raised its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Get Rating) by 104.6% during the 4th quarter, …

WebMar 14, 2024 · A look at the shareholders of Intra-Cellular Therapies, Inc. ... Meanwhile, the second and third largest shareholders, hold 8.8% and 7.3%, of the shares … the very reluctant convertWebOct 26, 2024 · Unfortunately, investing is risky - companies can and do go bankrupt. But if you pick the right business to buy shares... the very reverend andrew tremlettWebMar 14, 2024 · A look at the shareholders of Intra-Cellular Therapies, Inc. ( NASDAQ:ITCI ) can tell us which group is most powerful... the very reverendWebNov 5, 2024 · We're pleased to report that Intra-Cellular Therapies shareholders have received a total shareholder return of 15% over one year. Having said that, the five-year … the very reverend canonWebOct 17, 2024 · Intra-Cellular Therapies Inc. (ITCI) - free report >> Denali Therapeutics Inc. (DNLI) - free report >> Published in medical pharmaceuticals. Zacks' 7 Best Strong Buy Stocks for April, 2024. the very reverend brian horlockWeb104 rows · Apr 11, 2024 · Who are the largest shareholders of ITCI shares? During the previous two years, 289 institutional investors and hedge funds held shares of Intra … the very reverend dr robert willisWebApr 12, 2024 · Intra-Cellular Therapies stock opened at $58.70 on Wednesday. Intra-Cellular Therapies, Inc. has a 1-year low of $42.01 and a 1-year high of $65.98. The firm has a market capitalization of $5.59 ... the very reverend meaning